Drug profile · INN
omeprazole magnesium
PRILOSEC OTC
omeprazole magnesium (PRILOSEC OTC) is a potassium-transporting atpase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — omeprazole magnesium
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 7
- Programs
- 1
- Data quality
- 0.84
Quick answer
omeprazole magnesium (PRILOSEC OTC) is a potassium-transporting atpase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Potassium-transporting ATPase inhibitor
Primary target: Potassium-transporting ATPase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 11931463
All-in-one fixed-dose combination for treating Helicobacter pylori infection
granted -
US 11878011
Method for eradicating Helicobacter pylori infection in patients regardless of body mass index
granted -
US 11135172
Rifabutin-based compositions and methods for treating Helicobacter pylori infection
granted -
US 10238606
Pharmaceutical compositions for the treatment of Helicobacter pylori
granted -
US 9603806
Pharmaceutical compositions for the treatment of Helicobacter pylori
granted -
US 9498445
Pharmaceutical compositions for the treatment of Helicobacter pylori
granted -
US 9050263
Pharmaceutical compositions for the treatment of Helicobacter pylori
granted
Frequently asked questions
What is omeprazole magnesium?
omeprazole magnesium (PRILOSEC OTC) is a potassium-transporting atpase inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for omeprazole magnesium?
PRILOSEC OTC is a marketed brand name for omeprazole magnesium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of omeprazole magnesium?
omeprazole magnesium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.